Clearline Capital LP decreased its stake in shares of Stemline Therapeutics Inc (NASDAQ:STML) by 15.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 151,841 shares of the biopharmaceutical company’s stock after selling 27,239 shares during the quarter. Clearline Capital LP’s holdings in Stemline Therapeutics were worth $2,326,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in STML. Bank of America Corp DE boosted its holdings in shares of Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,866 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Stemline Therapeutics during the 1st quarter worth about $102,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Stemline Therapeutics during the 1st quarter worth about $36,000. Rhumbline Advisers boosted its holdings in shares of Stemline Therapeutics by 32.4% during the 1st quarter. Rhumbline Advisers now owns 49,184 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 12,046 shares during the period. Finally, TD Asset Management Inc. bought a new stake in shares of Stemline Therapeutics during the 1st quarter worth about $711,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Several analysts recently commented on the stock. BidaskClub downgraded shares of Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 10th. Wedbush raised shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a report on Friday, August 2nd. HC Wainwright set a $35.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Thursday, June 20th. ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Finally, Zacks Investment Research cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.50.

Stemline Therapeutics stock traded down $0.11 during midday trading on Thursday, hitting $11.45. The company’s stock had a trading volume of 21,076 shares, compared to its average volume of 627,068. Stemline Therapeutics Inc has a 1-year low of $7.82 and a 1-year high of $18.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.57. The company has a 50-day moving average price of $13.19 and a two-hundred day moving average price of $13.73. The company has a market cap of $480.43 million, a price-to-earnings ratio of -3.85 and a beta of 1.39.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.05. The business had revenue of $13.01 million during the quarter, compared to analyst estimates of $8.84 million. Sell-side analysts forecast that Stemline Therapeutics Inc will post -1.98 EPS for the current year.

In other news, CEO Ivan Bergstein sold 10,822 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $15.49, for a total value of $167,632.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kenneth Hoberman sold 9,107 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $141,067.43. The disclosure for this sale can be found here. Insiders sold a total of 158,370 shares of company stock valued at $2,383,666 in the last quarter. Corporate insiders own 13.10% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Article: Forex

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.